ABOUT THIS PROSPECTUS SUPPLEMENT
On March 29, 2018, we, as a well-known seasoned issuer as defined in Rule 405 under the Securities Act of 1933, as amended,
or the Securities Act, filed with the Securities and Exchange Commission, or SEC, an automatic registration statement on
Form S-3
(File
No. 333-224020),
which
registration statement became automatically effective upon filing. Under this shelf registration process, we may, from time to time, sell common stock and other securities, of which this offering is a part.
This document is in two parts. The first part is the prospectus supplement, including the documents incorporated by reference herein, which
describes the specific terms of this offering and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference. The second part, the accompanying prospectus, including the documents
incorporated by reference therein, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. Before you invest, you should
carefully read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, as well as the additional information described in this prospectus supplement under Where You Can Find
Additional Information. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in
the accompanying prospectus or any documents incorporated by reference therein, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by
reference therein.
We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and
sales are permitted. The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must
inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in
connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.
We own various U.S. federal trademark registrations and applications and unregistered trademarks, including our corporate logo. This
prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference contain references to trademarks, service marks and trade names, including logos, artwork, and other visual displays, that may appear
without the
®
or
TM
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks or trade names. We do not intend our use or display of other companies trade names, service marks or trademarks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement, accompanying prospectus or any related free writing
prospectus are the property of their respective owners.
Unless the context otherwise indicates, references in this prospectus supplement
to Audentes Therapeutics, we, our, us and the Company refer, collectively, to Audentes Therapeutics, Inc., a Delaware corporation.